标签归档：cgp

“-”开口硅胶片白色灭菌适用于96孔PCR板CGP-9-IMP-WS-

发表于由

“-”开口硅胶片白色灭菌适用于96孔PCR板

  • 产品型号：CGP-9-IMP-WS-
  • 简要描述：“-“开口硅胶片白色灭菌适用于96孔PCR板上海金畔生物科技有限公司供应：光度计，检测仪，免疫仪，全系荧光定量PCR耗材，移液器，钻石吸嘴，离心管，冻存管，培养皿，培养板，培养瓶，吸头，仪器及手套，色谱耗材，针头过滤器。
产品咨询在线客服
  • 产品简介

“-”开口硅胶片白色灭菌适用于96孔PCR板上海金畔生物科技有限公司供应：光度计，检测仪，移液器，钻石吸嘴，离心管，冻存管，培养皿，全系荧光定量PCR耗材。

PCR 板      

CG编号   ：CGP-9-IMP-WS-

产品描述  ：PCR板硅胶片，适用于96孔PCR板，“-”开口，白色，灭菌，化学耐受型

包装规格  ： 10片/袋，5袋/箱(50片/箱）

“-”开口硅胶片白色灭菌适用于96孔PCR板相关产品推荐：

SR6190    PCR板封膜超薄透明    100张/盒    
SR6590    进口PCR板封膜超薄透明，可用于荧光定量qPCR    100张/盒    
CGP-9-W-    PCR板硅胶片，适用于96孔PCR板，“-”开口，白色    10片/袋，5袋/箱(50片/箱）    
CGP-9-WS-    PCR板硅胶片，适用于96孔PCR板，“-”开口，白色，灭菌    10片/袋，5袋/箱(50片/箱）    

23-P002-T    0.2ML 8联排实时荧光定量PCR管+盖，平盖 无DNA/RNA酶 无热源 白色    125 条/盒, 10盒/箱     
23-2083    0.2ml 8联排PCR管+盖，凸盖，透明， 超薄壁, 非灭菌    125 套/盒, 10盒/箱 （1250套/箱）    
23-2084    0.2ml 12联排实时荧光定量PCR管+盖，透明，超薄壁, 平盖,非灭菌    200套/盒，10盒/箱    
23-2084-1    0.2ml 12联排PCR管+盖，凸盖，透明， 超薄壁, 非灭菌    200套/盒，10盒/箱    
23-2086    0.2mlPCR单管，薄壁，透明，平盖，非灭菌    1000支/包，10包/箱（10000支/箱）    
23-2085    0.5mlPCR单管，薄壁，透明，平盖，非灭菌    1000支/包，10包/箱（10000支/箱）    
进口PCR            
L-2081    0.2ml 8联排超薄清晰PCR管, 无DNA酶无RNA酶无热源, 无色.       125 条/包, 10包/箱    
L-2082    0.2ml 8联排管盖, 拱顶盖(凸盖), 无DNA酶无RNA酶无热源, 无色.      125 条/包 10盒/箱 (包装在L-2081 箱内)    
L-2087    0.2ml 8联排实时荧光定量PCR管,  超薄壁 无DNA酶无RNA酶无热源, 无色.     125 条/盒, 10盒/箱     
L-2088    0.2ml 8联排实时荧光定量PCR管盖, 平盖, 无DNA酶无RNA酶无热源, 无色.     125条/包，10包/箱 (包装在L-2087 箱内)    
PCR板            
23-2197N    200μl 96孔无裙边 PCR 板，透明，非灭菌    10块/袋，5袋/箱(50块/箱）    
23-35601    200μl 96孔半裙边 PCR 板，透明，非灭菌    10块/袋，5袋/箱(50块/箱）    
23-35601B    200μl 96孔半裙边 PCR 板，黑色，非灭菌    10块/袋，5袋/箱(50块/箱）    适应客户：医院检验科PCR实验室，中心实验室，肝病中心；第三方检测机构，科研院所，大专院校，制药厂，试剂生产厂家，疾控中心，检验检疫。 

 

注：主要经营地点—江浙沪！！产品其他相关详情请电询！

“-”开口PCR板白色硅胶片,适用于96孔PCR板CGP-9-IMP-W-

发表于由

“-”开口PCR板白色硅胶片,适用于96孔PCR板

  • 产品型号：CGP-9-IMP-W-
  • 简要描述：“-“开口PCR板白色硅胶片,适用于96孔PCR板上海金畔生物科技有限公司供应：光度计，检测仪，免疫仪，全系荧光定量PCR耗材，移液器，钻石吸嘴，离心管，冻存管，培养皿，培养板，培养瓶，吸头，仪器及手套，色谱耗材，针头过滤器。
产品咨询在线客服
  • 产品简介

“-”开口PCR板白色硅胶片,适用于96孔PCR板上海金畔生物科技有限公司供应：光度计，检测仪，移液器，钻石吸嘴，离心管，冻存管，培养皿，全系荧光定量PCR耗材。

PCR 板      

CG编号   ：CGP-9-IMP-W-

产品描述  ：PCR板硅胶片，适用于96孔PCR板，“-”开口，白色，化学耐受型

包装规格  ： 10片/袋，5袋/箱(50片/箱）

“-”开口PCR板白色硅胶片,适用于96孔PCR板相关产品推荐：

SR6190    PCR板封膜超薄透明    100张/盒    
SR6590    进口PCR板封膜超薄透明，可用于荧光定量qPCR    100张/盒    
CGP-9-W-    PCR板硅胶片，适用于96孔PCR板，“-”开口，白色    10片/袋，5袋/箱(50片/箱）    
CGP-9-WS-    PCR板硅胶片，适用于96孔PCR板，“-”开口，白色，灭菌    10片/袋，5袋/箱(50片/箱）    

货号    产品名称    颜色    包装规格    单位    
单管                    
V101-C    0.1ml PCR平盖单管    透明    1000个/盒，10盒/箱    盒    
VB201-C    0.2ml PCR平盖带托架单管    透明    1000个/盒，10盒/箱    盒    
V201-C    0.2ml PCR平盖单管    透明    1000个/盒，10盒/箱    盒    
V221-C    0.2ml PCR凸盖单管    透明    1000个/盒，10盒/箱    盒    
V-UCS    荧光定量PCR光学封板膜    高透明    10张/包    包    
辅助器                    
V-96AD    Roche 480辅助器    棕色    1块/包    块    96孔板                    

VP1011-C    0.1ml 无裙边96孔PCR板    透明    10块/盒，20盒/箱    盒    
VP1011-M    0.1ml 无裙边96孔PCR板    乳白色    10块/盒，20盒/箱    盒    
VP1021-C    0.1ml半裙边96孔PCR板    透明    10块/盒，20盒/箱    盒    
VP1031-C    0.1ml全裙边96孔PCR板    透明    10块/盒，20盒/箱    盒    
VP2001-C    0.2ml 无裙边96孔PCR板    透明    10块/盒，20盒/箱    盒    
VP2011-C    0.2ml 半裙边96孔PCR板    透明    10块/盒，20盒/箱    盒    
VP2021-C    0.2ml 半裙边96孔PCR板    透明    10块/盒，20盒/箱    盒    
VP2031-C    0.2ml 无裙边96孔上凸PCR板    透明    10块/盒，20盒/箱    盒    
V4801-M    Roche48096孔PCR板    乳白色    10块/盒，20盒/箱    盒    
V4802-M    Roche9696孔PCR板    乳白色    10块/盒，20盒/箱    盒    
V3841-M    40ul全裙边384孔PCR板    透明加白色    10块/盒，20盒/箱    盒    

适应客户：医院检验科PCR实验室，中心实验室，肝病中心；第三方检测机构，科研院所，大专院校，制药厂，试剂生产厂家，疾控中心，检验检疫。 

 

注：主要经营地点—江浙沪！！产品其他相关详情请电询！

CGP78850

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

CGP78850 

CGP78850 是 Grb2 SH2-phosphopeptide 相互作用的有力和选择性竞争者。CGP78850可用于癌症研究。

CGP78850

CGP78850 Chemical Structure

CAS No. : 258326-83-9

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

CGP78850 is a potent and selective competitor of Grb2 SH2-phosphopeptide interactions. CGP78850 can be used for the research of cancer[1].

IC50 & Target

Grb2 SH2-phosphopeptide[1]
体外研究
(In Vitro)

CGP78850 (0~100 μM; 90 minutes; MDA-MB-468 cells) reduces the amount of associated Grb2 protein in a dose-dependent manner[1].
CGP78850 blocks epidermal growth factor receptor (EGFR)-Grb2 and Shc-Grb2 interaction in living cells. CGP78850 inhibits MDA-MB-468 cells to form colonies in soft agar in a dose-dependent manner[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line: MDA-MB-468 cells
Concentration: 0~100 μM
Incubation Time: 90 minutes
Result: Reduced the amount of associated Grb2 protein in a dose-dependent manner.

分子量

723.75

Formula

C36H46N5O9P
CAS 号

258326-83-9
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Gay B, et al. Selective GRB2 SH2 inhibitors as anti-Ras therapy. Int J Cancer. 1999;83(2):235-241.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

CGP78850

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

CGP78850 

CGP78850 是 Grb2 SH2-phosphopeptide 相互作用的有力和选择性竞争者。CGP78850可用于癌症研究。

CGP78850

CGP78850 Chemical Structure

CAS No. : 258326-83-9

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

CGP78850 is a potent and selective competitor of Grb2 SH2-phosphopeptide interactions. CGP78850 can be used for the research of cancer[1].

IC50 & Target

Grb2 SH2-phosphopeptide[1]
体外研究
(In Vitro)

CGP78850 (0~100 μM; 90 minutes; MDA-MB-468 cells) reduces the amount of associated Grb2 protein in a dose-dependent manner[1].
CGP78850 blocks epidermal growth factor receptor (EGFR)-Grb2 and Shc-Grb2 interaction in living cells. CGP78850 inhibits MDA-MB-468 cells to form colonies in soft agar in a dose-dependent manner[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line: MDA-MB-468 cells
Concentration: 0~100 μM
Incubation Time: 90 minutes
Result: Reduced the amount of associated Grb2 protein in a dose-dependent manner.

分子量

723.75

Formula

C36H46N5O9P
CAS 号

258326-83-9
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Gay B, et al. Selective GRB2 SH2 inhibitors as anti-Ras therapy. Int J Cancer. 1999;83(2):235-241.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

CGP78850

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

CGP78850 

CGP78850 是 Grb2 SH2-phosphopeptide 相互作用的有力和选择性竞争者。CGP78850可用于癌症研究。

CGP78850

CGP78850 Chemical Structure

CAS No. : 258326-83-9

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

CGP78850 is a potent and selective competitor of Grb2 SH2-phosphopeptide interactions. CGP78850 can be used for the research of cancer[1].

IC50 & Target

Grb2 SH2-phosphopeptide[1]
体外研究
(In Vitro)

CGP78850 (0~100 μM; 90 minutes; MDA-MB-468 cells) reduces the amount of associated Grb2 protein in a dose-dependent manner[1].
CGP78850 blocks epidermal growth factor receptor (EGFR)-Grb2 and Shc-Grb2 interaction in living cells. CGP78850 inhibits MDA-MB-468 cells to form colonies in soft agar in a dose-dependent manner[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line: MDA-MB-468 cells
Concentration: 0~100 μM
Incubation Time: 90 minutes
Result: Reduced the amount of associated Grb2 protein in a dose-dependent manner.

分子量

723.75

Formula

C36H46N5O9P
CAS 号

258326-83-9
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Gay B, et al. Selective GRB2 SH2 inhibitors as anti-Ras therapy. Int J Cancer. 1999;83(2):235-241.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

CGP77675 hydrate

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

CGP77675 hydrate 

CGP77675 hydrate 是一种口服有效的 Src 家族激酶抑制剂。CGP77675 hydrate 抑制肽底物的磷酸化和纯化 Src 的自磷酸化 (IC50 分别为 5-20 和 40 nM)，并且还抑制 Src，EGFR，KDR，v-Abl 和 Lck，IC50 分别为 0.02、0.15、1.0、0.31 和 0.29 μM。具有抗肿瘤活性。

CGP77675 hydrate

CGP77675 hydrate Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

CGP77675 hydrate 的其他形式现货产品:

CGP77675

生物活性

CGP77675 hydrate is an orally active and potent inhibitor of Src family kinases. CGP77675 hydrate inhibits phosphorylation of peptide substrates and autophosphorylation of purified Src (IC50s of 5-20 and 40 nM, respectively),and also inhibits Src, EGFR, KDR, v-Abl, and Lck with IC50s of 0.02, 0.15, 1.0, 0.31, and 0.29 μM, respectively. Anticancer activity[1].

IC50 & Target

IC50: 0.02 μM (Src), 0.15 μM (EGFR), 1.0 μM (KDR), 0.31 μM (v-Abl), 0.29 μM (Lck)[1]
体外研究
(In Vitro)

CGP77675 hydrate dose dependently inhibits phosphorylation of poly-Glu-Tyr with an IC50 value of 5.5 nM, and of the optimal Src substrate (OSS) peptide with an IC50 value of 16.7 nM. These IC50 values are similar to the value obtained with chicken Src (20 nM)[1].
CGP77675 hydrate inhibits the parathyroid hormone-induced bone resorption in rat fetal long bone cultures with an IC50 of 0.8 μM[1].
CGP77675 hydrate (0.04-10 μM; 2 hours) potently inhibits tyrosine phosphorylation of the Src substrates Fak and paxillin, but has much less effect on Src (IC50 values 0.2, 0.5, and 5.7μM) in IC8.1 cells[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: MC3T3-E1 cells
Concentration: 0.2, 1, and 5 μM
Incubation Time: 3 days
Result: Did not influence cell viability for up to 3 days of treatment.

Western Blot Analysis[1]

Cell Line: Src-overexpressing IC8.1 cells
Concentration: 0.04, 0.2, 1, 5, and 10 μM
Incubation Time: 2 hours
Result: Dose dependently inhibited phosphorylation of Fak and paxillin, but not of Src.

体内研究
(In Vivo)

CGP77675 hydrate (1, 5, and 25 mg/kg; injected s.c.; twice a day) inhibits IL-1β-induced hypercalcemia in Mice[1].
CGP77675 hydrate (10 and 50 mg/kg; administered orally; twice a day for 6 weeks) partially prevents bone loss and rescues bone microarchitectural features in young ovx rats[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male mice (Tif:MAGf; Novartis Animal Farm) of 25-30 g body[1]
Dosage: 1, 5, and 25 mg/kg
Administration: Injected s.c.; twice a day
Result: Prevented IL-1β-induced hypercalcemia in mice without affecting serum amyloid protein levels.
Animal Model: Eight-week-old (175-209 g) female rats of the Sprague-Dawley-derived strain Tif:RAlf[1]
Dosage: 10 and 50 mg/kg
Administration: Administered orally; twice a day for 6 weeks
Result: Partly prevented bone loss.

Formula

C26H29N5O2.xH2O
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Missbach M, et al. A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellularsubstrates and reduces bone resorption in vitro and in rodent models in vivo. Bone. 1999 May;24(5):437-49.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

CGP77675 hydrate

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

CGP77675 hydrate 

CGP77675 hydrate 是一种口服有效的 Src 家族激酶抑制剂。CGP77675 hydrate 抑制肽底物的磷酸化和纯化 Src 的自磷酸化 (IC50 分别为 5-20 和 40 nM)，并且还抑制 Src，EGFR，KDR，v-Abl 和 Lck，IC50 分别为 0.02、0.15、1.0、0.31 和 0.29 μM。具有抗肿瘤活性。

CGP77675 hydrate

CGP77675 hydrate Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

CGP77675 hydrate 的其他形式现货产品:

CGP77675

生物活性

CGP77675 hydrate is an orally active and potent inhibitor of Src family kinases. CGP77675 hydrate inhibits phosphorylation of peptide substrates and autophosphorylation of purified Src (IC50s of 5-20 and 40 nM, respectively),and also inhibits Src, EGFR, KDR, v-Abl, and Lck with IC50s of 0.02, 0.15, 1.0, 0.31, and 0.29 μM, respectively. Anticancer activity[1].

IC50 & Target

IC50: 0.02 μM (Src), 0.15 μM (EGFR), 1.0 μM (KDR), 0.31 μM (v-Abl), 0.29 μM (Lck)[1]
体外研究
(In Vitro)

CGP77675 hydrate dose dependently inhibits phosphorylation of poly-Glu-Tyr with an IC50 value of 5.5 nM, and of the optimal Src substrate (OSS) peptide with an IC50 value of 16.7 nM. These IC50 values are similar to the value obtained with chicken Src (20 nM)[1].
CGP77675 hydrate inhibits the parathyroid hormone-induced bone resorption in rat fetal long bone cultures with an IC50 of 0.8 μM[1].
CGP77675 hydrate (0.04-10 μM; 2 hours) potently inhibits tyrosine phosphorylation of the Src substrates Fak and paxillin, but has much less effect on Src (IC50 values 0.2, 0.5, and 5.7μM) in IC8.1 cells[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: MC3T3-E1 cells
Concentration: 0.2, 1, and 5 μM
Incubation Time: 3 days
Result: Did not influence cell viability for up to 3 days of treatment.

Western Blot Analysis[1]

Cell Line: Src-overexpressing IC8.1 cells
Concentration: 0.04, 0.2, 1, 5, and 10 μM
Incubation Time: 2 hours
Result: Dose dependently inhibited phosphorylation of Fak and paxillin, but not of Src.

体内研究
(In Vivo)

CGP77675 hydrate (1, 5, and 25 mg/kg; injected s.c.; twice a day) inhibits IL-1β-induced hypercalcemia in Mice[1].
CGP77675 hydrate (10 and 50 mg/kg; administered orally; twice a day for 6 weeks) partially prevents bone loss and rescues bone microarchitectural features in young ovx rats[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male mice (Tif:MAGf; Novartis Animal Farm) of 25-30 g body[1]
Dosage: 1, 5, and 25 mg/kg
Administration: Injected s.c.; twice a day
Result: Prevented IL-1β-induced hypercalcemia in mice without affecting serum amyloid protein levels.
Animal Model: Eight-week-old (175-209 g) female rats of the Sprague-Dawley-derived strain Tif:RAlf[1]
Dosage: 10 and 50 mg/kg
Administration: Administered orally; twice a day for 6 weeks
Result: Partly prevented bone loss.

Formula

C26H29N5O2.xH2O
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Missbach M, et al. A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellularsubstrates and reduces bone resorption in vitro and in rodent models in vivo. Bone. 1999 May;24(5):437-49.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

CGP77675 hydrate

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

CGP77675 hydrate 

CGP77675 hydrate 是一种口服有效的 Src 家族激酶抑制剂。CGP77675 hydrate 抑制肽底物的磷酸化和纯化 Src 的自磷酸化 (IC50 分别为 5-20 和 40 nM)，并且还抑制 Src，EGFR，KDR，v-Abl 和 Lck，IC50 分别为 0.02、0.15、1.0、0.31 和 0.29 μM。具有抗肿瘤活性。

CGP77675 hydrate

CGP77675 hydrate Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

CGP77675 hydrate 的其他形式现货产品:

CGP77675

生物活性

CGP77675 hydrate is an orally active and potent inhibitor of Src family kinases. CGP77675 hydrate inhibits phosphorylation of peptide substrates and autophosphorylation of purified Src (IC50s of 5-20 and 40 nM, respectively),and also inhibits Src, EGFR, KDR, v-Abl, and Lck with IC50s of 0.02, 0.15, 1.0, 0.31, and 0.29 μM, respectively. Anticancer activity[1].

IC50 & Target

IC50: 0.02 μM (Src), 0.15 μM (EGFR), 1.0 μM (KDR), 0.31 μM (v-Abl), 0.29 μM (Lck)[1]
体外研究
(In Vitro)

CGP77675 hydrate dose dependently inhibits phosphorylation of poly-Glu-Tyr with an IC50 value of 5.5 nM, and of the optimal Src substrate (OSS) peptide with an IC50 value of 16.7 nM. These IC50 values are similar to the value obtained with chicken Src (20 nM)[1].
CGP77675 hydrate inhibits the parathyroid hormone-induced bone resorption in rat fetal long bone cultures with an IC50 of 0.8 μM[1].
CGP77675 hydrate (0.04-10 μM; 2 hours) potently inhibits tyrosine phosphorylation of the Src substrates Fak and paxillin, but has much less effect on Src (IC50 values 0.2, 0.5, and 5.7μM) in IC8.1 cells[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: MC3T3-E1 cells
Concentration: 0.2, 1, and 5 μM
Incubation Time: 3 days
Result: Did not influence cell viability for up to 3 days of treatment.

Western Blot Analysis[1]

Cell Line: Src-overexpressing IC8.1 cells
Concentration: 0.04, 0.2, 1, 5, and 10 μM
Incubation Time: 2 hours
Result: Dose dependently inhibited phosphorylation of Fak and paxillin, but not of Src.

体内研究
(In Vivo)

CGP77675 hydrate (1, 5, and 25 mg/kg; injected s.c.; twice a day) inhibits IL-1β-induced hypercalcemia in Mice[1].
CGP77675 hydrate (10 and 50 mg/kg; administered orally; twice a day for 6 weeks) partially prevents bone loss and rescues bone microarchitectural features in young ovx rats[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male mice (Tif:MAGf; Novartis Animal Farm) of 25-30 g body[1]
Dosage: 1, 5, and 25 mg/kg
Administration: Injected s.c.; twice a day
Result: Prevented IL-1β-induced hypercalcemia in mice without affecting serum amyloid protein levels.
Animal Model: Eight-week-old (175-209 g) female rats of the Sprague-Dawley-derived strain Tif:RAlf[1]
Dosage: 10 and 50 mg/kg
Administration: Administered orally; twice a day for 6 weeks
Result: Partly prevented bone loss.

Formula

C26H29N5O2.xH2O
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Missbach M, et al. A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellularsubstrates and reduces bone resorption in vitro and in rodent models in vivo. Bone. 1999 May;24(5):437-49.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务